Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury
Abstract
1. Introduction
2. Results
3. Discussion
4. Conclusions
5. Materials and Methods
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Weld, K.J.; Dmochowski, R.R. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology 2000, 55, 490–494. [Google Scholar] [CrossRef]
- Kuo, H.-C.; Chen, S.-L.; Chou, C.-L.; Chuang, Y.-C.; Huang, Y.-H.; Juan, Y.-S.; Lee, W.-C.; Liao, C.-H.; Tsai, Y.-C.; Tsai, Y.-A.; et al. Clinical guidelines for the diagnosis and management of neurogenic lower urinary tract dysfunction. Tzu Chi Med. J. 2014, 26, 103–113. [Google Scholar] [CrossRef]
- Cruz, F. Targets for botulinum toxin in the lower urinary tract. Neurourol. Urodyn. 2014, 33, 31–38. [Google Scholar] [CrossRef]
- Kanai, A.; Zabbarova, I.; Oefelein, M.; Radziszewski, P.; Ikeda, Y.; Andersson, K.-E. Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011. Neurourol. Urodyn. 2012, 31, 300–308. [Google Scholar] [CrossRef]
- Schulte-Baukloh, H.; Priefert, J.; Knispel, H.H.; Lawrence, G.W.; Miller, K.; Neuhaus, J. Botulinum Toxin A Detrusor Injections Reduce Postsynaptic Muscular M2, M3, P2X2, and P2X3 Receptors in Children and Adolescents Who Have Neurogenic Detrusor Overactivity: A Single-blind Study. Urology 2013, 81, 1052–1057. [Google Scholar] [CrossRef] [PubMed]
- Smith, C.P.; Vemulakonda, V.M.; Kiss, S.; Boone, T.B.; Somogyi, G.T. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: Effect of botulinum toxin A. Neurochem. Int. 2005, 47, 291–297. [Google Scholar] [CrossRef] [PubMed]
- Smith, C.P.; Gangitano, D.A.; Munoz, A.; Salas, N.A.; Boone, T.B.; Aoki, K.R.; Francis, J.; Somogyi, G.T. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem. Int. 2008, 52, 1068–1075. [Google Scholar] [CrossRef]
- Yiangou, Y.; Facer, P.; Ford, A.; Brady, C.; Wiseman, O.; Fowler, C.; Anand, P. Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int. 2001, 87, 774–779. [Google Scholar] [CrossRef]
- Herschorn, S.; Gajewski, J.; Ethans, K.; Corcos, J.; Carlson, K.; Bailly, G.; Bard, R.; Valiquette, L.; Baverstock, R.; Carr, L.; et al. Efficacy of botulinum toxin a injection for neurogenic detrusor overactivity and urinary incontinence: A randomized, double-blind trial. J. Urol. 2011, 185, 2229–2235. [Google Scholar] [CrossRef]
- Cruz, F.; Herschorn, S.; Aliotta, P.; Brin, M.; Thompson, C.; Lam, W.; Daniell, G.; Heesakkers, J.; Haag-Molkenteller, C. Efficacy and safety of onabotulinumtoxina in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. Eur. Urol. 2011, 60, 742–750. [Google Scholar] [CrossRef]
- Ginsberg, D.; Gousse, A.; Keppenne, V.; Sievert, K.-D.; Thompson, C.; Lam, W.; Brin, M.F.; Jenkins, B.; Haag-Molkenteller, C. Phase 3 efficacy and tolerability study of onabotulinumtoxina for urinary incontinence from neurogenic detrusor overactivity. J. Urol. 2012, 187, 2131–2139. [Google Scholar] [CrossRef] [PubMed]
- Rovner, E.; Kohan, A.; Chartier-Kastler, E.; Jünemann, K.-P.; Del Popolo, G.; Herschorn, S.; Joshi, M.; Magyar, A.; Nitti, V. Long-Term efficacy and safety of onabotulinumtoxina in patients with neurogenic detrusor overactivity who completed 4 years of treatment. J. Urol. 2016, 196, 801–808. [Google Scholar] [CrossRef] [PubMed]
- Sussman, D.; Patel, V.; Del Popolo, G.; Lam, W.; Globe, D.; Pommerville, P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxina in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol. Urodyn. 2013, 32, 242–249. [Google Scholar] [CrossRef]
- Li, G.-P.; Wang, X.-Y.; Zhang, Y. Efficacy and safety of onabotulinumtoxina in patients with neurogenic detrusor overactivity caused by spinal cord injury: A systematic review and meta-analysis. Int. Neurourol. J. 2018, 22, 275–286. [Google Scholar] [CrossRef] [PubMed]
- Ni, J.; Wang, X.; Cao, N.; Si, J.; Gu, B. Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity-A systematic review and meta-analysis. Neurourol. Urodyn. 2018, 37, 542–553. [Google Scholar] [CrossRef] [PubMed]
- Kennelly, M.; Dmochowski, R.; Schulte-Baukloh, H.; Ethans, K.; Del Popolo, G.; Moore, C.; Jenkins, B.; Guard, S.; Zheng, Y.; Karsenty, G. Efficacy and safety of onabotulinumtoxina therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourol. Urodyn. 2017, 36, 368–375. [Google Scholar] [CrossRef] [PubMed]
- Elkelini, M.S.; Bagli, D.J.; Fehlings, M.; Hassouna, M. Effects of intravesical onabotulinumtoxina on bladder dysfunction and autonomic dysreflexia after spinal cord injury: Role of nerve growth factor. Br. J. Urol. 2012, 109, 402–407. [Google Scholar] [CrossRef]
- Jia, C.; Liao, L.-M.; Chen, G.; Sui, Y. Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury. Spinal Cord 2013, 51, 487–490. [Google Scholar] [CrossRef]
- Baron, M.; Peyronnet, B.; Aublé, A.; Hascoet, J.; Castel-Lacanal, E.; Miget, G.; Le Doze, S.; Prudhomme, T.; Manunta, A.; Cornu, J.-N.; et al. Long-term discontinuation of botulinum toxin a intradetrusor injections for neurogenic detrusor overactivity: A multicenter study. J. Urol. 2018, 201, 769–776. [Google Scholar] [CrossRef] [PubMed]
- Kuo, H.-C. Therapeutic outcome and quality of life between urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia. Int. J. Clin. Pract. 2013, 67, 1044–1049. [Google Scholar] [CrossRef] [PubMed]
- Leitner, L.; Guggenbühl-Roy, S.; Knüpfer, S.C.; Walter, M.; Schneider, M.P.; Tornic, J.; Sammer, U.; Mehnert, U.; Kessler, T.M. More than 15 years of experience with intradetrusor onabotulinumtoxina injections for treating refractory neurogenic detrusor overactivity: Lessons to be learned. Eur. Urol. 2016, 70, 522–528. [Google Scholar] [CrossRef]
- Chen, C.-Y.; Liao, C.-H.; Kuo, H.-C. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia. Spinal Cord 2011, 49, 659–664. [Google Scholar] [CrossRef]
- Ginsberg, D.; Cruz, F.; Herschorn, S.; Gousse, A.; Keppenne, V.; Aliotta, P.; Sievert, K.D.; Brin, M.F.; Jenkins, B.; Thompson, C.; et al. onabotulinumtoxina is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology. Adv. Ther. 2013, 30, 819–833. [Google Scholar] [CrossRef] [PubMed]
- Hebert, K.P.; Klarskov, N.; Bagi, P.; Biering-Sørensen, F.; Elmelund, M. Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury. Spinal Cord 2020, 58, 675–681. [Google Scholar] [CrossRef]
- Chen, S.-F.; Kuo, H.-C. Therapeutic outcome and patient adherence to repeated onabotulinumtoxina detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity. J. Formos. Med. Assoc. 2015, 114, 583–589. [Google Scholar] [CrossRef] [PubMed]
- Koschorke, M.; Leitner, L.; Sadri, H.; Knüpfer, S.C.; Mehnert, U.; Kessler, T.M. Intradetrusor onabotulinumtoxina injections for refractory neurogenic detrusor overactivity incontinence: Do we need urodynamic investigation for outcome assessment? BJU Int. 2017, 120, 848–854. [Google Scholar] [CrossRef]
- Lombardi, G.; Musco, S.; Bacci, G.; Celso, M.; Bellio, V.; Del Popolo, G. Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury. Int. Braz J. Urol 2017, 43, 721–729. [Google Scholar] [CrossRef][Green Version]
- Wu, S.-Y.; Kuo, H.-C. A real-world experience with augmentation enterocystoplasty-High patient satisfaction with high complication rates. Neurourol. Urodyn. 2018, 37, 744–750. [Google Scholar] [CrossRef]
- Anquetil, C.; Abdelhamid, S.; Gelis, A.; Fattal, C. Botulinum toxin therapy for neurogenic detrusor hyperactivity versus augmentation enterocystoplasty: Impact on the quality of life of patients with SCI. Spinal Cord 2016, 54, 1031–1035. [Google Scholar] [CrossRef] [PubMed]
- Lai, E.C.-C.; Yang, Y.-H.K.; Kuo, H.-C. Complication rate of neurogenic lower urinary tract dysfunction after spinal cord injury in Taiwan. Int. Urol. Nephrol. 2014, 46, 1063–1071. [Google Scholar] [CrossRef]
- Chartier-Kastler, E.; Rovner, E.; Hepp, Z.; Khalaf, K.; Ni, Q.; Chancellor, M. Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity. Neurourol. Urodyn. 2016, 35, 595–600. [Google Scholar] [CrossRef]
- Noordhoff, T.C.; Groen, J.; Scheepe, J.R.; Blok, B.F. Surgical Management of Anatomic Bladder Outlet Obstruction in Males with Neurogenic Bladder Dysfunction: A Systematic Review. Eur. Urol. Focus 2018, 5, 875–886. [Google Scholar] [CrossRef]
- Fougere, R.J.; Currie, K.D.; Nigro, M.K.; Stothers, L.; Rapoport, D.; Krassioukov, A.V. Reduction in bladder-related autonomic dysreflexia after onabotulinumtoxina tratment in spinal cord injury. J. Neurotrauma 2016, 33, 1651–1657. [Google Scholar] [CrossRef]
- Ginsberg, D.A.; Boone, T.B.; Cameron, A.P.; Gousse, A.; Kaufman, M.R.; Keays, E.; Kennelly, M.J.; Lemack, G.E.; Rovner, E.S.; Souter, L.H.; et al. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-up. J. Urol. 2021, 206, 1106–1113. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.-F.; Jiang, Y.-H.; Jhang, J.-F.; Lee, C.-L.; Kuo, H.-C. Bladder management and urological complications in patients with chronic spinal cord injuries in Taiwan. Tzu Chi Med. J. 2014, 26, 25–28. [Google Scholar] [CrossRef]
- Abrams, P.; Cardozo, L.; Fall, M.; Griffiths, D.; Rosier, P.; Ulmsten, U.; van Kerrebroeck, P.; Victor, A.; Wein, A. Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-Committee of the International Continence Society. Neurourol. Urodyn. 2002, 21, 167–178. [Google Scholar] [CrossRef]
- Chen, Y.-C.; Kuo, H.-C. The Therapeutic Effects of Repeated Detrusor Injections Between 200 or 300 Units of OnabotulinumtoxinA in Chronic Spinal Cord Injured Patients. Neurourol. Urodyn. 2014, 33, 129–134. [Google Scholar] [CrossRef] [PubMed]
Patient Characteristics | N | Not Improved | Mildly Improved | Moderately Improved | Markedly Improved | p Value * |
---|---|---|---|---|---|---|
Male | 154 | 24 (15.6%) | 30 (19.5%) | 64 (41.6%) | 36 (23.4%) | 0.109 |
Female | 69 | 11 (15.9%) | 21 (30.4%) | 17 (24.6%) | 20 (29.0%) | |
Cervical SCI | 89 | 10 (11.2%) | 19 (21.3%) | 36 (40.4%) | 24 (27.0%) | 0.045 |
Thoracic SCI | 115 | 18 (15.7%) | 27 (23.5%) | 42 (36.5%) | 28 (24.3%) | |
Lumbar and sacral | 19 | 7 (36.8%) | 5 (26.3%) | 3 (15.8%) | 4 (21.1%) | |
Complete SCI | 185 | 25 (13.5%) | 43 (23.2%) | 70 (37.8%) | 47 (25.4%) | 0.221 |
Incomplete SCI | 38 | 10 (28.6%) | 8 (21.1%) | 11 (28.9%) | 9 (23.7%) | |
With AD | 145 | 28 (19.3%) | 36 (24.8%) | 45 (31.0%) | 36 (24.8%) | 0.02 |
No AD | 78 | 7 (9.0%) | 15 (19.2%) | 36 (46.2%) | 20 (25.6%) | |
Hand Function Normal | ||||||
Partial | 161 | 28 (17.4%) | 40 (24.8%) | 53 (32.9%) | 40 (24.8%) | 0.013 |
Incapable * | 23 | 3 (13.0%) | 8 (34.8%) | 6 (26.1%) | 6 (26.1%) | |
39 | 4 (10.3%) | 3 (7.7%) | 22 (56.4%) | 10 (25.6%) |
Urodynamic Parameters | 1. Not Improved | 2. Mildly Improved | 3. Moderately Improved | 4. Markedly Improved | p Value | |
---|---|---|---|---|---|---|
All | 3 + 4 | |||||
Age | 43.6 ± 15.1 | 43.1 ± 14.4 | 37.6 ± 14.0 | 38.8 ± 14.8 | 0.071 | 0.009 |
Duration | 6.9 ± 8.1 | 7.1 ± 8.0 | 6.4 ± 7.0 | 7.3 ±7.9 | 0.920 | 0.809 |
FSF (mL) | 147 ± 101 | 120 ± 80.0 | 114 ± 75.1 | 107 ± 66.8 | 0.118 | 0.072 |
FS (mL) | 207 ± 116 | 163 ± 102 | 159 ± 102 | 127 ± 72.6 | 0.003 | 0.011 |
US (mL) | 228 ± 133 | 177 ± 113 | 180 ± 115 | 134 ± 76.3 | 0.010 | 0.018 |
Compliance | 59.7 ± 83.8 | 57.7 ± 74.9 | 37.4 ± 48.5 | 34.8 ± 55.0 | 0.090 | 0.021 |
Pdet (cmH2O) | 19.1 ± 16.1 | 25.8 ±12.6 | 37.0 ± 17.6 | 58.5 ± 23.2 | All | <0.0001 |
Qmax (mL/s) | 7.31 ± 6.87 | 5.27 ± 7.05 | 4.59 ± 5.14 | 4.80 ± 4.72 | 0.126 | 0.101 |
Volume(mL) | 110 ± 124 | 68.5 ± 99.1 | 63.5 ± 82.6 | 76.2 ± 90.9 | 0.117 | 0.242 |
PVR(mL) | 203 ± 187 | 163 ± 168 | 193 ± 176 | 126 ± 112 | 0.065 | 0.554 |
VE (%) | 43.0 ± 39.4 | 33.8 ± 35.2 | 30.8 ± 32.1 | 39.7 ± 35.5 | 0.269 | 0.520 |
BCI | 55.7 ± 394 | 52.1 ± 41.9 | 59.9 ± 32.7 | 82.5 ± 36.8 | All | <0.0001 |
BOOI | 4.51 ± 20.0 | 15.2 ± 14.7 | 27.8 ± 19.4 | 48.9 ± 23.0 | All | <0.0001 |
VUDS Characteristics | N | Not Improved | Mildly Improved | Moderately Improved | Markedly Improved | p Value |
---|---|---|---|---|---|---|
NDO, No DSD | 13 | 6 (46.2%) | 4 (30.8%) | 2 (15.4%) | 1 (7.7%) | <0.0001 |
NDO, with DSD | 150 | 11 (7.3%) | 36 (24.0%) | 56 (37.3%) | 47 (31.3%) | |
NDO + BND + DSD | 39 | 6 (15.4%) | 9 (23.1%) | 18 (46.2%) | 6 (15.4%) | |
DU + low compliance | 19 | 10 (52.6%) | 2 (10.5%) | 5 (26.3%) | 2 (10.5%) | |
DU + ISD | 2 | 2 (100%) | 0 | 0 | 0 | |
Low pressure | 102 | 29 (28.4%) | 35 (34.3%) | 31 (30.4%) | 7 (6.9%) | <0.0001 |
High pressure | 118 | 4 (3.4%) | 16 (13.6%) | 49 (41.5%) | 49 (41.5%) | |
Equivocal | 3 | 2 (66.7%) | 0 (0%) | 1 (33.3%) | 0 (0%) |
Bladder Management | N * | 1. Not Improved | 2. Mildly Improved | 3. Moderately Improved | 4. Markedly Improved | p Value * | |
---|---|---|---|---|---|---|---|
All | 3 + 4 | ||||||
Detrusor Botox/CIC | 108 | 11 (10.2%) | 20 (18.5%) | 49 (45.4%) | 28 (25.9%) | 0.014 | 0.003 |
AE | 29 | 4 (13.8%) | 7 (24.1%) | 10 (34.5%) | 8 (27.6%) | 0.976 | 0.940 |
Ileal conduit | 1 | 0 | 0 | 0 | 1 (100%) | 0.637 | 0.386 |
Urethral Botox | 24 | 4 (16.7%) | 6 (25.0%) | 8 (33.3%) | 6 (25.0%) | 0.987 | 0.741 |
TUI-BN | 9 | 3 (33.3%) | 2 (22.2%) | 3 (33.3%) | 1 (11.1%) | 0.452 | 0.312 |
TUI-P/TUR-P | 6 | 0 | 1 (16.7%) | 3 (50.0%) | 2 (33.3%) | 0.840 | 0.410 |
Suburethral sling | 5 | 2 (40.0%) | 1 (20.0%) | 2 (40.0%) | 0 | 0.345 | 0.376 |
Cystostomy | 8 | 3 (37.5%) | 2 (25.0%) | 1 (12.5%) | 2 (25.0%) | 0.223 | 0.266 |
Indwelling catheter | 14 | 1 (7.1%) | 4 (28.6%) | 6 (42.9%) | 3 (21.4%) | 0.834 | 0.821 |
CIC alone | 11 | 3 (27.3%) | 2 (18.2%) | 1 (9.1%) | 5 (45.5%) | 0.099 | 0.753 |
External sphincterotomy | 1 | 0 | 0 | 0 | 1 (100%) | 0.637 | 1.000 |
Self-voiding and medication | 88 | 17 (19.3%) | 24 (27.3%) | 26 (29.5%) | 21 (23.9%) | 0.224 |
Bladder Management | N * | Satisfied to Current Status | Acceptable Wish to Change | Not Satisfied but No Change | p Value * |
---|---|---|---|---|---|
Detrusor Botox/CIC | 108 | 82 (75.9%) | 15 (13.9%) | 11 (10.2%) | <0.0001 |
AE | 29 | 24 (82.8%) | 2 (6.9%) | 3 (10.3%) | 0.170 |
Ileal conduit | 1 | 1 (100%) | 0 | 0 | 1.000 |
Urethral Botox | 24 | 15 (62.5%) | 8 (33.3%) | 1 (4.2%) | 0.060 |
TUI-BN | 9 | 4 (44.4%) | 3 (33.3%) | 2 (22.2%) | 0.355 |
TUI-P/TUR-P | 6 | 6 (100%) | 0 | 0 | 0.343 |
Suburethral sling | 5 | 3 (60.0%) | 2 (40.0%) | 0 | 0.390 |
Cystostomy | 8 | 2 (25.0%) | 5 (62.5%) | 1 (12.5%) | 0.017 |
Indwelling catheter | 14 | 9 (64.3%) | 3 (21.4%) | 2 (14.3%) | 0.889 |
CIC alone | 11 | 7 (63.6%) | 2 (18.2%) | 2 (18.2%) | 1.000 |
External sphincterotomy | 1 | 1 (100%) | 0 | 0 | 1.000 |
Self-voiding and medication | 88 | 44 (50%) | 13 (14.8%) | 31 (35.2%) | <0.0001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chen, S.-F.; Jiang, Y.-H.; Jhang, J.-F.; Kuo, H.-C. Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury. Toxins 2022, 14, 35. https://doi.org/10.3390/toxins14010035
Chen S-F, Jiang Y-H, Jhang J-F, Kuo H-C. Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury. Toxins. 2022; 14(1):35. https://doi.org/10.3390/toxins14010035
Chicago/Turabian StyleChen, Sheng-Fu, Yuan-Hong Jiang, Jia-Fong Jhang, and Hann-Chorng Kuo. 2022. "Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury" Toxins 14, no. 1: 35. https://doi.org/10.3390/toxins14010035
APA StyleChen, S.-F., Jiang, Y.-H., Jhang, J.-F., & Kuo, H.-C. (2022). Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury. Toxins, 14(1), 35. https://doi.org/10.3390/toxins14010035